drugset / Trial / NCT01732211
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
RandomizedParallel-groupTriple-blindBasic science
Summary
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
Timeline
- Start
- 2013-03-15
- Primary completion
- 2013-09-23
- Completion
- 2013-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PD 0360324 | Monoclonal antibody | 100 mg | Intravenous |
| Subject | PD 0360324 | Monoclonal antibody | 150 mg | Intravenous |